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Type I interferon in systemic autoimmune diseases
Th   e hypothesis that type I interferon plays a central role 
in the pathogenesis of systemic lupus erythematosus 
(SLE) has gained growing support in recent years [1-4]. 
Th  e early data from the 1970s demonstrating increased 
functional interferon activity in lupus patient sera have 
been conﬁ  rmed and extended using current technologies 
that permit detection of the broad gene expression 
program induced by type I interferons [5-8]. Expression 
of an interferon signature – reﬂ  ecting expression of often 
more than 100 type I interferon-inducible genes in peri-
pheral blood mononuclear cells (PBMC) – is also seen in 
highly related syndromes characterized by systemic 
autoimmunity, including Sjögren’s syndrome [9]. In 
addition, clinical observations from patients treated with 
recombinant IFNα for control of hepatitis C infection or 
malignancy indicate that in some individuals, possibly 
determined by their harboring genetic susceptibility 
factors that aug  ment response to interferon, auto  anti-
bodies character  istic of SLE can develop [10,11]. 
Occasion  ally clinical features that represent at least four 
of the American College of Rheumatology classiﬁ  cation 
criteria for diag  nosis of SLE develop in those patients.
Th   e occurrence of clinical syndromes more charac  ter-
istic of inﬂ   ammatory diseases distinct from SLE in 
patients treated with therapeutic IFNα has gained less 
attention. Nonetheless, numerous case reports and case 
series describe inﬂ  ammatory arthritis, multiple sclerosis 
(MS) or diabetes that develops during the course of inter-
feron therapy [12-15]. As in the case of the lupus-like 
syn  dromes, the capacity of IFNα to promote those 
diseases that are typically considered to have strong 
inﬂ  am  matory components suggests that type I interferon 
might also play a pathogenic role in diseases such as 
rheumatoid arthritis (RA), MS or type I diabetes mellitus 
(DM). Th   e data supporting increased expression of IFNα 
and interferon-inducible genes in those diseases is less 
well developed than in the prototype systemic auto-
immune disease SLE or in Sjögren’s syndrome, which 
shares some autoantibody speciﬁ   cities and immune 
system alterations with SLE [16].
Confusing our understanding of the role of type I inter-
ferons in these other diseases that are characterized by 
systemic autoimmunity as well as pathology and clinical 
manifestations focused on an organ system (RA: 
diarthodial joints; MS: myelin sheath in the central 
nervous system; and DM: insulin-producing β cells in the 
pancreas) is the fact that type I interferons have been 
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A signifi  cant role for IFNα in the pathogenesis of 
systemic lupus erythematosus is well supported, and 
clinical trials of anti-IFNα monoclonal antibodies are in 
progress in this disease. In other autoimmune diseases 
characterized by substantial infl  ammation and tissue 
destruction, the role of type I interferons is less clear. 
Gene expression analysis of peripheral blood cells 
from patients with rheumatoid arthritis and multiple 
sclerosis demonstrate an interferon signature similar to 
but less intense than that seen in patients with lupus. 
In both of those diseases, presence of the interferon 
signature has been associated with more signifi  cant 
clinical manifestations. At the same time, evidence 
supports an anti-infl  ammatory and benefi  cial role of 
IFNβ locally in the joints of patients with rheumatoid 
arthritis and in murine arthritis models, and many 
patients with multiple sclerosis show a clinical response 
to recombinant IFNβ. As can also be proposed for 
type I diabetes mellitus, type I interferon appears to 
contribute to the development of autoimmunity and 
disease progression in multiple autoimmune diseases, 
while maintaining some capacity to control established 
disease – particularly at local sites of infl  ammation. 
Recent studies in both rheumatoid arthritis and 
multiple sclerosis suggest that quantifi  cation of type I 
interferon activity or target gene expression might be 
informative in predicting responses to distinct classes 
of therapeutic agents.
© 2010 BioMed Central Ltd
Type I interferon in organ-targeted autoimmune 
and infl  ammatory diseases
Mary K Crow*
REVIEW
*Correspondence: crowm@hss.edu
Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Cornell 
Medical College, 535 East 70th Street, New York, NY 10021, USA
Crow Arthritis Research & Therapy 2010, 12(Suppl 1):S5 
http://arthritis-research.com/content/12/S1/S5
© 2010 BioMed Central Ltdpostulated to be either potential or current therapies for 
those diseases based on their anti-inﬂ  ammatory proper  ties 
or on clinical experience that suggested some eﬃ   cacy. Th  e 
present review will describe data demon  strating activation 
of the type I interferon pathway in these inﬂ  ammatory 
diseases that target speciﬁ  c organs, and will attempt to 
sort out the relative roles of type I inter  ferons, particularly 
IFNα and IFNβ, as pathogenic mediators versus attractive 
therapeutic agents in those diseases.
Against the background of extensive data from patients 
with SLE, and more recently from murine lupus models 
[17], that demonstrate an association of interferon 
pathway activation with more severe disease and disease 
activity [18], the common and accepted use of recombi-
nant IFNβ, alone or in combination with ribavirin, in 
patients with MS presents a conundrum [19]. If type I 
interferon is broadly pathogenic in systemic autoimmune 
diseases, why is IFNβ beneﬁ  cial in patients with MS? A 
similar question can be asked with regard to RA, where 
IFNβ has been demonstrated in the synovial membranes 
of RA patients and in several murine models of inﬂ  am-
matory arthritis but is proposed to be anti-inﬂ  ammatory 
and protective rather than pathogenic [20-23]. Possible 
explanations for these queries include the following: 
IFNα and IFNβ have distinct properties that confer 
distinct functional eﬀ  ects on gene expression and the 
immune system; the pathophysiology of the classic sys-
temic autoimmune diseases is substantially distinct from 
the pathophysiology of the autoimmune diseases that are 
characterized by inﬂ  ammation focused in speciﬁ  c organs; 
and the complex roles of both IFNα and IFNβ in host 
defense and immunoregulation allow for each of the 
interferons to play pathogenic and protective roles, 
depending on site of production or action, the disease 
context in which they act, or other factors (Figure. 1). It is 
likely that each of these explanations accounts in part for 
the reality that type I interferon does contribute to 
autoimmune disease pathogenesis but can also control 
inﬂ  ammation in some situations.
Common and distinct properties of IFNα and IFNβ
Th  e type I interferons are encoded in series on human 
chromosome 9p. Th   ere are 13 functional IFNα genes, one 
IFNβ gene, one IFNκ gene encoding a protein that is 
preferentially expressed in skin, one IFNε gene that is 
expressed in placenta and fetal membranes, and one 
IFNω gene [24]. All of the protein products of the type I 
interferon family bind to a single heterodimeric receptor 
composed of IFNAR1 and IFNAR2. Consideration of a 
potential pathogenic or protective role for individual type 
I interferons, particularly IFNα and IFNβ, involves under-
standing the cell types that might preferentially produce 
these interferons, the distinct binding properties of IFNα 
and IFNβ for the type I interferon receptor (IFNAR), and 
whether these interferons engage distinct signaling path-
ways and activate distinct target genes.
While classic teaching holds that IFNβ is most eﬀ  ect-
ively produced by ﬁ  broblasts and that IFNα is primarily 
produced by plasmacytoid dendritic cells, many cell types 
can in fact produce both interferons, particularly in the 
setting of a viral stimulus [25]. Diﬀ  erential production of 
one or another type I interferon in diﬀ  erent contexts is 
probably in part cell-type related but also determined by 
the location of those cells [21,23,26,27]. IFNβ is produced 
by synoviocytes and keratinocytes, and in small amounts 
by monocyte-derived cells. IFNκ, a type I interferon that 
has attracted less attention than IFNβ and IFNα, is 
apparently predominantly made by keratinocytes, based 
on available data [28]. IFNβ-producing cells are located 
in tissue linings, and IFNβ can also be produced by 
stromal cells through a novel pathway that involves 
activation of lymphotoxin-β receptors [29].
In contrast, plasmacytoid dendritic cells are located in 
peripheral lymphoid organs and, at least in disease 
settings, in organs aﬀ  ected by inﬂ  ammation. In view of 
the widespread distribution and circulating nature of 
plasmacytoid dendritic cells, situations in which IFNα is 
produced expose the host to systemic type I interferon 
and might contribute to autoimmunity, while situations 
in which IFNβ is produced might result in more localized 
rather than systemic concentrations of the cytokine and 
abrogate inﬂ  ammation. At least one mechanism by which 
local type I interferon might reduce inﬂ  ammation has 
been suggested to be through inhibitory eﬀ  ects on TNF 
production [30,31].
Th   e binding properties of each of the IFNα and IFNβ 
proteins for IFNAR1 can vary, depending on interaction 
of the cytokine with deﬁ  ned amino acids of the receptor 
[32]. Th   e availability of signaling components of the Jak-
Stat pathway can also impact the functional results of one 
of the type I interferons binding to its receptor. For 
example, absence of Tyk2 inhibits IFNα-mediated signal-
ing but does not alter IFNβ-mediated signaling [33]. Th  e 
downstream gene targets induced by IFNα and IFNβ 
appear to be highly similar, although some studies have 
demonstrated that IFNβ is more potent than IFNα in 
inducing gene expression [34]. Taken together, data 
comparing properties and functional eﬀ  ects of IFNα and 
IFNβ would suggest that the most important contributors 
to diﬀ  erential eﬀ  ects of those two type I interferons relate 
to the location of production (predominantly local in the 
case of IFNβ and systemic in the case of IFNα) and to 
aﬃ   nity of the interaction of interferon with the receptor 
and its impact on proximal signaling pathways.
Rheumatoid arthritis
Recent studies of gene expression in blood and synovial 
membranes from RA patients suggest that certain 
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[35,36]. Of interest, a pathogen-response gene expression 
program characterized by increased expression of type I 
interferon-inducible genes was identiﬁ  ed in a subgroup 
of RA patients who also expressed high circulating anti-
cyclic citrullinated peptide antibody levels, the auto-
antibodies associated with more destructive RA [35,36]. 
A recent demonstration of an association between the 
interferon signature and progression to arthritis in 
patients with arthralgias and anti-cyclic citrullinated 
peptide antibodies further supports a probable patho-
genic role for type I interferon in RA, perhaps based on 
the tendency for systemic type I interferon to promote 
autoantibody formation [37].
In contrast, the potential relevance of type I interferon, 
and more speciﬁ  cally IFNβ, produced locally in the joint 
as a protective factor in RA is suggested by in vitro 
studies of RA synovial membrane and experiments in 
murine models of inﬂ   ammatory arthritis. In collagen-
induced and adjuvant arthritis models, intraperitoneal or 
intraarticular injection of IFNβ resulted in reduction of 
disease activity and inhibition of cartilage and bone 
destruction through a signiﬁ  cant decrease of TNF and 
IL-6 expression and an enhancement of IL-10 responses 
at the site of inﬂ  ammation [20,38,39]. Type I interferon 
might also positively aﬀ   ect arthritis by inhibiting the 
diﬀ   erentiation of monocytes into osteoclasts, thereby 
reducing bone resorption and erosions [40].
Studies of human tissue have indicated that IFNβ is 
present in RA synovial membranes and reduces synovio-
cyte proliferation in vitro – observations that have led to 
the suggestion that IFNβ is an anti-inﬂ  ammatory media-
tor with a protective role in RA [21-23]. Adminis  tration 
of recombinant IFNβ in the context of a randomized, 
double-blind, placebo-controlled clinical trial for treat-
ment of patients with active RA, however, showed no 
treatment eﬀ  ect with regard to clinical or radiographic 
scores [41]. Since synovial tissue from the patients who 
received the IFNβ therapy did not show a signiﬁ  cant 
diﬀ   erence in numbers of inﬁ   ltrating myeloid cells or 
T cells compared with the placebo group, it is possible 
that the dose or timing of IFNβ administration did not 
deliver suﬃ   cient cytokine to the joint to demonstrate an 
anti-inﬂ  ammatory eﬀ  ect.
Figure 1. IFNα is predominantly a product of the peripheral immune system. In systemic lupus erythematosus (SLE), IFNα is produced at high 
levels and has systemic eff  ects on multiple immune system pathways, promoting autoimmunity and infl  ammation. A more modest level of IFNα 
might also contribute to autoimmunity in type I diabetes mellitus (DM), multiple sclerosis (MS) and rheumatoid arthritis (RA), as demonstrated by 
data from murine models and an interferon-inducible gene signature in blood. IFNβ is produced in small amounts by myeloid cells but probably 
has its greatest impact locally where it is produced by fi  broblasts and stromal cells. Type I interferon-inducible gene products, such as IL-10 and IL-1 
receptor antagonist (IL-1ra), produced locally can blunt infl  ammation.
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associated with anti-inﬂ  ammatory activities in the setting 
of RA, and in view of the variable expression of an inter-
feron signature among RA patients [35,36], we postulated 
that expression of type I interferon might represent a 
positive predictor of response to TNF-antagonist therapy 
in RA patients, while low levels of type I interferon might 
identify RA patients who would be candidates for alter-
native therapeutic options. To investigate this hypothesis, 
type I interferon activity was determined in plasma 
samples from a previously described RA cohort [42] prior 
to and during the course of TNF-antagonist therapy.
We showed that RA patients collectively express 
increased plasma type I interferon activity relative to 
levels in healthy controls [43]. Th  e most signiﬁ  cant 
obser  vation, and one that will require conﬁ  rmation in 
larger populations, was that higher levels of type I 
interferon activity prior to therapy with TNF inhibitors 
are associated with better outcomes as deﬁ  ned by the 
European League Against Rheumatism (EULAR) RA 
improve  ment criteria [43]. In view of the data showing a 
protective role for IFNβ in murine models of inﬂ  am  ma-
tory arthritis, we looked at which interferon was the 
major contributor to plasma type I interferon activity in 
the RA patients. Inhibition experiments using mono-
clonal anti-IFNα and anti-IFNβ antibodies revealed that 
both IFNα and IFNβ contribute to type I interferon 
activity in RA plasma [43]. Th   is observation is in contrast 
to SLE, where anti-IFNβ antibodies have little eﬀ  ect on 
plasma type I interferon activity [44]. Moreover, a higher 
IFNβ/IFNα ratio prior to initiation of TNF inhibitor 
therapy was found to be associated with a better clinical 
response, pointing to IFNβ, rather than IFNα, as a key 
contributor to control of inﬂ  ammation and predictor for 
a better response to TNF-antagonist therapy.
IFNβ has pleiotropic immunomodulatory actions – 
including decreased expression of the proinﬂ  ammatory 
cytokines IL-1β and TNFα, and enhancement of the anti-
inﬂ  ammatory cytokines IL-1 receptor antagonist, IL-10, 
and transforming growth factor beta [45-48]. IFNβ has 
also been shown to mediate inhibition of MHC class II 
expression on activated PBMC [48], inhibition of T-cell 
activation [49] and decreased expression of adhesion 
molecules [50]. Since IL-1 receptor antagonist, an anti-
inﬂ   ammatory cytokine, can be induced by IFNβ, we 
measured IL-1 receptor antagonist levels in RA patient 
samples. A statistically signiﬁ  cant association was detec-
ted between baseline IL-1 receptor antagonist levels and 
therapeutic outcome, pointing to an elevated plasma IL-1 
receptor antagonist level as an additional predictor of 
good response in TNF inhibitor-treated patients [43].
Perhaps consistent with our results, a report from 
Sekiguchi and colleagues described variability in peri-
pheral blood gene expression of RA patients treated with 
inﬂ  iximab. Although not reaching statistical signiﬁ  cance, 
there was a trend toward increased expression of 
interferon-inducible genes prior to initiation of treatment 
in those patients who went on to respond to therapy as 
determined by meeting an American College of 
Rheumatology 50% improvement response rate at week 
22 [51]. Gene expression patterns over time were variable 
among responders and nonresponders and with time 
after initiation of therapy, with a typical decrease in 
interferon-inducible gene expression at the 2-week time 
point followed by an increase in some patients.
A recent report from Van Baarsen and colleagues 
described data derived from whole-blood, real-time PCR 
analysis of a panel of interferon-response genes in RA 
patients treated with inﬂ   iximab [52]. Th  at group also 
observed a range of baseline values and changes after 
initiation of therapy. Rather than comparing patients 
based on EULAR clinical response criteria, these investi-
gators segregated patients into two groups based on the 
ratio of their interferon-inducible gene expression scores 
before and after 1 month of therapy. Th   ose patients who 
showed an increase in type I interferon-inducible gene 
expression at 1 month tended to have a poor clinical 
response to treatment as determined at 16 weeks. 
Analysis of a subset of their patients identiﬁ  ed as EULAR 
responders or nonresponders supported this trend. Th  is 
pattern of an increase in interferon pathway activation in 
TNF antagonist nonresponders is consistent with our 
earlier study of Sjögren’s syndrome patients, in which we 
observed a general increase in plasma type I interferon 
activity at 12 weeks after start of therapy in patients 
treated with etanercept but not in those who received 
placebo [16]. No conclusion could be reached regarding 
the relationship of interferon activity to therapeutic 
response as the etanercept treatment was not eﬃ   cacious 
in those patients. Our laboratory is currently conducting 
studies to determine the distinct gene expression proﬁ  le 
induced by plasma from patients who show a clinical 
response to TNF inhibitors compared with those patients 
who do not show a good clinical response.
Taken together, the available data support a relationship 
between type I interferon activity or interferon-inducible 
gene expression and eﬀ  ects of TNF blockade, with at 
least a trend toward higher levels of type I interferon 
prior to therapy being associated with a clinical response, 
and suggest that early incremental increase in interferon-
inducible gene expression compared with baseline levels 
might predict poor response to therapy.
While TNF inhibitors have been highly successful in 
improv  ing clinical outcomes for patients with RA, some 
patients do not respond. Additional therapeutic 
approaches have been approved for patients who prove 
to be TNF inhibitor nonresponders – including treatment 
with rituximab, the B-cell-depleting monoclonal 
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our collaborators suggest that in contrast to our results 
showing superior responses to TNF inhibitor therapy in 
patients with increased plasma type I interferon activity 
at baseline, those patients who show a superior response 
to anti-B-cell therapy have low levels of type I interferon 
at baseline [53]. While it would be clinically useful to 
have a bio  marker that permitted selection of a thera-
peutic approach that would prove most eﬀ  ective based 
on measurement of type I interferon levels, it is very 
likely that the nature of RA, the complexity of the genetic 
contributors to therapeutic response, and the variability 
in the complement of mediators produced in each patient 
will not allow a simple predictive test. Nonetheless, 
distinct relationships of systemic type I interferon levels 
in patients who respond to TNF inhibitors compared 
with those who respond to anti-B-cell therapy should 
stimulate new concepts regarding mechanisms of disease 
pathogenesis.
Multiple sclerosis
Th  e moderate eﬃ   cacy of recombinant IFNβ in patients 
with MS suggests the obvious conclusion that type I 
interferon is therapeutic rather than pathogenic in that 
disease [19]. It should be noted, however, that the clinical 
development programs which led to the approval of IFNβ 
did not deﬁ  ne its mechanism of action. Nor has it been 
clear whether IFNβ oﬀ  ers a beneﬁ  t diﬀ  erent from that 
seen after administration of IFNα. In fact, the diﬀ  erential 
eﬀ  ects of IFNα and IFNβ are diﬃ   cult to demonstrate. In 
general, the gene expression programs that are induced 
by IFNα versus IFNβ are largely overlapping [34]. While 
subtle diﬀ  erences in the binding properties of each of the 
interferons to IFNAR, their common receptor, have been 
predicted based on analysis of their amino acid sequence 
and mutation studies, and there are demonstrated diﬀ  er-
ences in engaging downstream signaling compo  nents by 
the two type I interferon subtypes, their func  tional 
impact on gene expression is quite comparable [32-34].
In light of the frequent administration of therapeutic 
IFNβ, it is perhaps surprising that gene expression 
analysis of patients with relapsing remitting multiple 
sclerosis (RRMS) (untreated with IFNβ) has demon-
strated an interferon signature similar to the more classic 
signature seen in many patients with SLE [31,54,55]. Van 
Baarsen and colleagues were among the ﬁ  rst to discern 
the typical signature reﬂ  ecting type I interferon activation 
in whole blood in their study of 29 patients with RRMS 
and 25 healthy controls [54]. Along with a signature of 
immunoglobulin-related transcripts, one of the most 
prominent groups of transcripts was enriched in 
interferon-induced genes. Th   e authors performed several 
analyses of the diﬀ   erentially expressed genes in their 
dataset in comparison with genes deﬁ  ned as either type I 
or type II (IFNγ)-inducible based on data in the literature, 
and concluded that type I interferon-inducible genes 
were increased in RRMS patients compared with control 
subjects whereas type II-induced genes were comparable 
between the two groups.
Van Baarsen and colleagues went further, however, and 
analyzed the gene program with a view towards predict-
ing whether bacteria – which tend to activate the immune 
response through NF-κB-activating TLR2 or TLR4 path-
ways – or viruses – which tend to activate the immune 
response through TLR3, TLR7 or TLR9 path  ways and 
utilize MyD88 – are more likely to be respon  sible for the 
gene program observed in the patients. Th  e NF-κB 
program was not diﬀ  erent between patients and controls, 
but the interferon-induced gene program, similar to that 
induced by viruses, was diﬀ   erentially expressed. Th  e 
study also compared the pattern of over  expressed genes 
in the RRMS patients with those induced in macaques by 
smallpox infection, and found that more than 50% of the 
patients clustered with the virus-infected macaques. Th  e 
diﬀ   erentially expressed genes that characterized this 
subset of RRMS patients corresponded to those that 
describe a common response pathway characterizing 
innate immune responses to microbes [54].
A role for type I interferon in RRMS is also supported 
by demonstration of IFNα, IFNβ, and MxA protein in 
brain lesions of patients with MS [56-58]. In acute 
lesions, astrocytes stained positive for IFNβ, macro-
phages expressed more IFNα, and endothelial cells some-
times expressed both IFNα and IFNβ. Chronic lesions 
were more likely to be positive for IFNα [56]. MXA, a 
type I interferon-inducible gene product, is present in 
astro  cytes, in inﬁ  ltrating T lymphocytes, and in endo-
thelial cells – and the presence of nearby plasmacytoid 
dendritic cells suggests that the interferon is produced 
locally [57,58]. MXA protein in peripheral blood of 
RRMS patients and elevated serum levels of type I 
interferon are also detected [55]. Since the assays used to 
detect type I interferon activity in MS sera are distinct 
from those that have been used by others to quantify that 
activity in SLE patients, the relative levels cannot be 
compared. Based on the requirement for IFNγ priming to 
detect MxA protein in IFNAR-positive WISH epithelial 
cells cultured with MS sera, however, it seems probable 
that the levels are likely to be lower in most MS patients 
than in SLE patients with detectable interferon activity. 
One interpretation of the data demonstrating local type I 
interferon and its induced protein products in MS brain 
is that the interferon is providing an immunosuppressive 
eﬀ  ect [56].
Th   e paradigm of IFNα promoting systemic auto  immu-
nity versus IFNβ reducing local inﬂ  ammatory disease as 
an approach to understanding the role of type I inter-
ferons might apply to patients with MS treated with 
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feron inhibits TNF production are data from a study of 
RRMS patients treated for 18 to 24 months with IFNβ 
compared with patients not treated with IFNβ [31]. 
IL-12, TNF, and IFNγ levels were elevated in the plasma 
or culture supernatants from MS patients compared with 
controls, but TNF and IFNγ levels were signiﬁ  cantly 
lower in patients treated with IFNβ compared with those 
not treated. Of interest, TNF levels in whole blood 
cultures stimulated with lipopolysaccharide and IFNγ in 
supernatants of cultures stimulated with myelin basic 
protein were not diﬀ  erent from levels in healthy controls 
in patients who had been treated with IFNβ, but did 
increase further in RRMS patients who had not been 
treated. At least in the case of the TNF data, the results 
would support an inhibitory eﬀ  ect of IFNβ downstream 
of TLR4 that reduces target gene expression.
A comprehensive analysis of IFNβ responders and 
nonresponders was recently published [59]. Th  e study 
analyzed 47 patients with RRMS (29 responders and 18 
nonresponders, with responders deﬁ   ned based on no 
increase in the Expanded Disability Status Sale and no 
relapses during 2 years of treatment). Comparison of 
baseline gene expression proﬁ   les in PBMC identiﬁ  ed 
diﬀ  erentially expressed genes in the two groups. Of great 
interest, type I interferon-inducible genes were generally 
overexpressed in the nonresponder patients and repre-
sented the pathway most signiﬁ   cantly associated with 
nonresponse to IFNβ. When assessed after 3 months of 
therapy, most IFNβ clinical responders showed a robust 
cellular response with increased expression of interferon-
inducible genes, while the nonresponder group showed 
modest or no increases in levels of expression of those 
genes. In fact, a prediction algorithm identifying the 
eight genes that best predicted IFNβ responders from 
non  responders included ﬁ   ve typical type I interferon-
inducible genes (IFIT1, IFIT2, IFIT3, IFI44, and OASL).
Th  e conclusions from the study of this initial cohort 
were validated in a second cohort including 15 respon-
ders and 15 nonresponders [59]. Consistent with the 
increased level of inter  feron-inducible gene transcripts in 
the non  responder group, baseline phosphorylated-
STAT1 levels were higher in nonresponder monocytes 
than in responder monocytes. In addition, type I 
interferon bioactivity was higher in the nonresponders 
than in responders or healthy donors. Th   e authors of this 
highly informative study performed in vitro stimulation 
experiments to compare signaling downstream of IFNAR 
as well as in response to TLR ligands, and found roughly 
comparable responses in the two patient groups – with 
the exception of production of IFNα in response to 
lipopolysaccharide, which was signiﬁ   cantly lower in 
responders than in nonresponders or healthy donors, as 
was expression of IFNAR1.
Th   e interpretation of these results suggests a complex 
role for the type I interferon system in MS: consistent 
with the Van Baarsen and colleagues study, a subset of 
RRMS showed a type I interferon signature in blood in 
the absence of treatment, with Comabella and colleagues 
showing increased bioactive type I interferon in the 
nonresponder group – an observation conﬁ   rmed in a 
recent report [59,60]. Th  e Comabella and colleagues 
study suggests that the high interferon group, those cases 
that do not respond to IFNβ, has an interferon pathway 
that is constitutively activated but is not further activated 
by administration of recombinant IFNβ. As the non-
responder group obviously has poorer outcomes than the 
IFNβ responders, one is led to the speculation that 
increased production of type I interferon in MS patients 
contributes to disease and refractoriness to therapy. 
Similar to mechanisms suggested relevant to SLE, mye-
loid dendritic cells in the nonresponder RRMS patients 
studied by Comabella and colleagues showed increased 
expression of the costimulatory molecule CD86, suggest-
ing that those cells might be capable of eﬀ  ective activa-
tion of self-reactive T cells.
One interpretation of the diﬀ  erent proﬁ  les in the IFNβ 
responders and nonresponders is that when presented 
with an innate immune stimulus (such as lipopoly  sac-
charide), the responder monocytes engage cellular 
mecha  nisms that reduce the capacity of the cells to 
produce type I interferon while the cells from non-
responder patients do not ramp down that pathway. 
Impaired production of inhibitors of the Jak-STAT 
pathways activated by interferon binding to IFNAR was 
not demonstrated by the authors, as SOCS1, SOCS2 and 
PIAS1 expression was comparable between responders 
and nonresponders. Taken together, the data draw 
attention to the regulatory mechanisms that modulate 
innate immune responses downstream of TLRs, with 
TLR4 the relevant pathway in the RRMS patients.
Consideration of the demonstrated increased type I 
interferon bioactivity, increased expression of interferon-
inducible genes, and stimulatory dendritic cell phenotype 
in IFNβ-treated patients who do not respond to that 
treatment raises the possibility that, similar to the 
situation in SLE, type I interferon might be a pathogenic 
mediator in that subset of RRMS patients and might be 
an appropriate therapeutic target. Additional studies that 
characterize this interesting nonresponder group more 
completely from the immunologic and serologic 
parameters will be of great interest. Although auto  anti-
bodies are not presumed to play as signiﬁ  cant  a 
pathogenic role in MS as T cells, it will be interesting to 
know whether the interferon high nonresponder group 
demonstrates higher levels of relevant autoantibodies 
than the interferon low responder group – as is the case 
in interferon high SLE patients [18]. Th  e induction of 
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diseases and could be a mechanism that contributes to 
increased humoral immunity. It will also be productive to 
compare T-cell responses to relevant self-antigens, such 
as myelin basic protein, in the IFN high group – the 
prediction being that self-reactive T cells will be 
expanded or more readily activated by antigen-presenting 
cells in those patients.
Th  e somewhat counterintuitive data presented by 
Comabella and colleagues leave hanging the issue of how 
IFNβ results in a beneﬁ  cial eﬀ  ect in those patients who 
do respond. One should note there is general agreement 
that recombinant IFNβ produces only modest responses 
in some patients. One prediction that could be tested 
using samples from the published study cohorts is that 
patients who go on to respond to IFNβ therapy are those 
with more robust TNF production. While the mecha-
nisms that account for inhibition of TNF by type I 
interferon are not fully elucidated, the cytokine data do 
show reduction in TNF in patients who complete 18 to 
24 months of IFNβ therapy, many of whom are 
presumably clinical responders [31]. Augmentation of 
IL-10 by IFNβ through an IFNγ-dependent pathway might 
also contribute to amelioration of disease activity [60].
Th  ere seem to be three categories of defect that are 
associated with the IFNβ nonresponder RRMS patients: 
production of interferon is high; in the setting of the in 
vivo stimuli that characterize MS, IFNAR1 expression and 
signaling through TLR4 are not reduced in the 
nonresponders as they are in the responders; and capacity 
to further activate transcription of type I interferon-
inducible genes is abrogated. Th   e latter alteration might be 
due to a system in overdrive in which all available 
transcription factors are engaged; in eﬀ  ect, the patient’s 
immune system is desensitized to further activation by 
IFNβ. It should be noted that extremely high-level expres-
sion of gene transcripts typically asso  ciated with inﬂ  am-
matory states, such as CXCL10 and PBEF1, achieves levels 
that are substantially higher in the responders after 3 months 
of IFNβ therapy [59]. Th  is concurrence of improved 
clinical activity and increased expression of proinﬂ  am-
matory mediators, at least at the transcript level, indicates 
that increased proinﬂ  ammatory gene expression does not 
necessarily translate into increased inﬂ  ammation. Perhaps 
the extremely high expres  sion of IL1RN (IL-1 receptor 
antagonist) transcripts in the treated responders provides 
balance that counters the proinﬂ  ammatory mediators.
Type I diabetes mellitus
If RA is an organ-focused systemic autoimmune and 
inﬂ  ammatory disease in which local type I interferon is 
primarily anti-inﬂ   ammatory, DM is an organ-targeted 
autoimmune disease in which type I interferon’s major 
role, at least in murine models, is pathogenic.
Stewart and colleagues were the ﬁ  rst to demonstrate 
the capacity of IFNα to promote diabetes in a mouse 
model [61]. Th   ey showed increased expression of MHC 
class II and costimulatory molecules in the pancreas and 
linked the induction of activated antigen-presenting cells 
to development of self-reactive T cells. Other investi-
gators have conﬁ  rmed the disease amplifying role of type 
I interferon in the nonobese diabetic murine diabetes 
model [62-64]. While direct data regarding type I 
interferon expression at the site of disease are limited in 
patients with DM, diabetes has been induced in those 
patients who have received therapeutic IFNα for hepatitis 
C – similar to the reports of development of lupus, 
inﬂ  ammatory arthritis or MS [65].
In view of the abundant data from murine models of 
diabetes demonstrating a probable pathogenic role for 
type I interferon, along with the induction of diabetes in 
some patients receiving IFNα, Stewart has suggested that 
inhibition of IFNα with a speciﬁ  c monoclonal antibody 
might be beneﬁ   cial [66]. An opposing view has been 
proposed by Brod, who has put forward the interesting 
concept that the three diseases reviewed – RA, MS and 
DM – represent IFNα deﬁ  ciency states, perhaps based on 
inadequate response to an undeﬁ  ned viral infection [67]. 
In that view, the high level expression of type I interferon 
and interferon-inducible genes would reﬂ   ect an active 
but insuﬃ   cient eﬀ  ort of the innate immune system to 
control a more primary inﬂ  ammatory process. With this 
idea in mind, Brod has conducted clinical trials in which 
IFNα is given in oral form to patients, with the hypothesis 
that the IFNα will generate immunosuppressive altera-
tions in immune function. Brod has demonstrated in a 
murine model that oral IFNα administration results in 
increased interferon-inducible gene expression in T 
lymphocytes [67]. In a study of patients with recent-onset 
DM, a trend toward preservation of pancreatic β-cell 
function was observed in those who received 5,000 units 
of recombinant IFNα by oral route daily, but not in those 
who received a higher dose, compared with those who 
received placebo [68]. No eﬀ  ect of treatment was seen in 
terms of hemoglobin A1c levels. Additional placebo-
controlled trials will be required to determine whether 
oral administration of low-dose IFNα has a therapeutic 
eﬀ  ect in autoimmune diseases.
Conclusions
In contrast to SLE – where a primary pathogenic role for 
IFNα in autoimmunity and disease pathogenesis is 
supported by data from studies of genetic polymorphisms 
that are associated with increased type I interferon, an 
interferon signature in PBMC, murine lupus studies in 
which IFNα accelerates disease, and preliminary data 
from human trials indicating a positive therapeutic 
response in some patients receiving anti-IFNα 
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in the three diseases reviewed. Some of the disease-
associated gene variants that have been associated with 
increased IFNα production in patients with SLE, such as 
IRF5, Tyk2 or PTPN22, have also shown an association 
with RA, MS or DM, but the associations are not as well 
documented in those diseases [69-73].
Data in the literature support a possible pathogenic 
role for type I interferon in RA, MS and DM, based on 
demonstration of an interferon signature in blood in RA 
and MS and based on data from murine models in the 
case of DM. At the same time, type I interferon appears 
to play an anti-inﬂ  ammatory protective role in the joint 
tissue of patients with RA and in several murine models 
of inﬂ  ammatory arthritis. Similarly, some patients with 
MS demonstrate a beneﬁ  cial therapeutic eﬀ  ect of IFNβ. 
Of note, those who show a positive clinical response tend 
to be those who do not demonstrate an interferon 
signature prior to therapy and whose PBMC are respon-
sive to type I interferon in vivo. In the case of both RA 
and MS, while systemic type I interferon might play a 
contributing role in induction of autoimmunity, its anti-
inﬂ  ammatory role might be more signiﬁ  cant. Studies in 
DM are less well developed, and whether blockade of 
type I interferon to inhibit expansion of the autoimmune 
process or administration of type I interferon to reduce 
destruction of β cells by an inﬂ  ammatory process or to 
inhibit replication of a putative virus would be more 
beneﬁ  cial will require further investigation.
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